Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms

Angelo B. A. Laranjeira, Tim Kong, Steven C. Snyder, Mary C. Fulbright, Daniel A. C. Fisher, Daniel T. Starczynowski, Stephen T. Oh

Blood (2024) 143 (23): 2414–2424.

https://doi.org/10.1182/blood.2023022804

Published: 2024

Includes: Supplemental data

Journal Articles

Kme-0584, a Highly Potent IRAK1/IRAK4/panFLT3 Inhibitor, Is a Promising Clinical Candidate for Hypomethylating Agent Plus Venetoclax Resistant AML/MDS Patients

Jan S. Rosenbaum, Amal S. Kolt, Scott B. Hoyt, Gregory M. Hayes, Brandi L. Soldo, Craig J. Thomas, Daniel T. Starczynowski

Blood (2023) 142 (Supplement 1): 4152.

https://doi.org/10.1182/blood-2023-189899

Published: 2023

Journal Articles

UBE2N Regulates Oncoprotein Networks in Myeloid Malignancies

Chiharu Ishikawa, Laura Barreyro, Avery Sampson, Kathleen Hueneman, Kwangmin Choi, Lyndsey C. Bolanos, Andrew Volk, Stephanie S Watowich, Kenneth Greis, Daniel T. Starczynowski

Blood (2023) 142 (Supplement 1): 2762.

https://doi.org/10.1182/blood-2023-187438

Published: 2023

Journal Articles

Regulation of Metabolic Homeostasis By TRAF6 Contributes to the Leukemia Progression

Shinichiro Matsui, Chihiro Ri, Lyndsey C. Bolanos, Kwangmin Choi, Asuka Shibamiya, Arata Ishii, Koji Takaishi, Nagisa Oshima-Hasegawa, Shokichi Tsukamoto, Yusuke Takeda, Naoya Mimura, Koutaro Yokote, Daniel T. Starczynowski, Emiko Sakaida, Tomoya Muto

Blood (2023) 142 (Supplement 1): 1370.

https://doi.org/10.1182/blood-2023-178962

Published: 2023

Journal Articles

The Mechanism of Therapy Resistance By Lineage Plasticity in AML and How to Overcome It

Sean Walulik, Sarai Dean, Eric J Vick, Xiaoqin Zhu, Mark Wunderlich, Chih-Hsing Chou, Kwangmin Choi, H. Leighton Grimes, Daniel T. Starczynowski, Linde A. Miles, Andrew Volk

Blood (2023) 142 (Supplement 1): 1410.

https://doi.org/10.1182/blood-2023-186180

Published: 2023

Journal Articles

In Vivo Ablation of NFκB Cascade Effectors Alleviates Disease Burden in Myeloproliferative Neoplasms

Angelo B. A. Laranjeira, Tim Kong, Steven Craig Snyder, Mary C. Fulbright, Daniel A.C. Fisher, Daniel T. Starczynowski, Stephen T. Oh

Blood (2023) 142 (Supplement 1): 991.

https://doi.org/10.1182/blood-2023-182290

Published: 2023

Journal Articles

Therapeutic Targeting of FLT3 Gate Keeper Mutation with E2082-0047 in Traditional and a Novel Immunocompetent Murine Adoptive Transfer Model of AML

Blood (2023) 142 (Supplement 1): 1544.

https://doi.org/10.1182/blood-2023-189259

Published: 2023

Journal Articles

The Zymogen Form of Caspase-1 Is Required to Fine Tune Excessive Cell-Intrinsic Inflammation in Acute Myeloid Leukemia

Emma E. Uible, Kwangmin Choi, Kathleen Hueneman, Lyndsey C. Bolanos, Kenneth Greis, Daniel T. Starczynowski

Blood (2023) 142 (Supplement 1): 1391.

https://doi.org/10.1182/blood-2023-187396

Published: 2023

Journal Articles

Defective Necroptosis Mediates Chemotherapy Resistance in AML

Ashley E. Cochran, Aishlin Hassan, Kathleen Hueneman, Kwangmin Choi, Daniel T. Starczynowski

Blood (2023) 142 (Supplement 1): 1394.

https://doi.org/10.1182/blood-2023-190061

Published: 2023

Journal Articles

Synthetic Lethal Interactions with IRAK4 Inhibition in Myeloid Malignancies

Eric J Vick, Josh Bennett, Ashley E. Cochran, Kathleen Hueneman, Lyndsey C. Bolanos, Xiaohu Zhang, Crystal McKnight, Michele Ceribelli, Carleen Klumpp-Thomas, Kwangmin Choi, Kenneth Greis, Craig J. Thomas, Daniel T. Starczynowski

Blood (2023) 142 (Supplement 1): 45.

https://doi.org/10.1182/blood-2023-177797

Published: 2023

Journal Articles

Targeting CREB-Binding Protein (CREBBP) Overcomes Resistance to Azacitidine and Venetoclax Therapy in Acute Myeloid Leukemia (AML)

Francis LeBlanc, Josh Bennett, Kwangmin Choi, Daniel T. Starczynowski

Blood (2023) 142 (Supplement 1): 5765.

https://doi.org/10.1182/blood-2023-187063

Published: 2023

Journal Articles

Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML

Joshua Bennett, Chiharu Ishikawa, Puneet Agarwal, Jennifer Yeung, Avery Sampson, Emma Uible, Eric Vick, Lyndsey C. Bolanos, Kathleen Hueneman, Mark Wunderlich, Amal Kolt, Kwangmin Choi, Andrew Volk, Kenneth D. Greis, Jan Rosenbaum, Scott B. Hoyt, Craig J. Thomas, Daniel T. Starczynowski

Blood (2023) 142 (11): 989–1007.

https://doi.org/10.1182/blood.2022018718

Published: 2023

Includes: Supplemental data

Journal Articles

TRIM13 Is a Novel Cell Cycle Hub Regulated By CHAF1B to Promote Acute Myeloid Leukemogenesis

Sarai Dean, Chiharu Ishikawa, Xiaoqin Zhu, Timothy Nixon, Sean Walulik, Michael Wyder, Jessica Jordan, Mark Wunderlich, Daniel T. Starczynowski, Nathan Salomonis, Ken Greis, Andrew Volk

Blood (2022) 140 (Supplement 1): 2978–2979.

https://doi.org/10.1182/blood-2022-169879

Published: 2022

Journal Articles

A Circulating Microbial Metabolite Drives the Clonal Expansion of Pre-Leukemic Cells

Puneet Agarwal, Avery Sampson, Kathleen Hueneman, Kwangmin Choi, Xueheng Zhao, Jessica Galloway-Pena, Kenneth Setchell, Daniel T. Starczynowski

Blood (2022) 140 (Supplement 1): 975–976.

https://doi.org/10.1182/blood-2022-159124

Published: 2022

Journal Articles

ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 9749–9750.

https://doi.org/10.1182/blood-2022-165298

Published: 2022

Journal Articles

IRAK1 Contributes to IRAK4 Inhibitor Resistance Via Non-Canonical Signaling Mechanisms in MDS/AML

Josh Bennett, Jennifer Yeung, Avery Sampson, Kathleen Hueneman, Mark Wunderlich, Kwangmin Choi, Andrew Volk, Scott B. Hoyt, Craig J. Thomas, Daniel T. Starczynowski

Blood (2022) 140 (Supplement 1): 2240–2241.

https://doi.org/10.1182/blood-2022-167526

Published: 2022

Journal Articles

Inhibition of Both IRAK1 and IRAK4 Is Required for Complete Suppression of NF-Kb Signaling across Multiple Receptor-Mediated Pathways in MDS and AML

Jan S Rosenbaum, Scott B. Hoyt, Amal S. Kolt, Daniel A Luedtke, Craig J. Thomas, Daniel T. Starczynowski

Blood (2022) 140 (Supplement 1): 5949–5950.

https://doi.org/10.1182/blood-2022-167783

Published: 2022

Journal Articles

UBE2N Is a Druggable Target and an Essential Ubiquitin-Conjugating Enzyme in Myeloid Malignancies

Chiharu Ishikawa, Laura Barreyro, Avery Sampson, Kathleen Hueneman, Kwangmin Choi, Lyndsey C Bolanos, Andrew Volk, Kenneth D Greis, Daniel T. Starczynowski

Blood (2022) 140 (Supplement 1): 5830.

https://doi.org/10.1182/blood-2022-167336

Published: 2022

Journal Articles

HHEX expression drives AML development

Daniel T. Starczynowski

Blood (2020) 136 (14): 1575–1576.

https://doi.org/10.1182/blood.2020007049

Published: 2020

Journal Articles

Cell-Intrinsic Inflammation Drives Progression from Myelodysplastic Syndromes to Leukemia

Laura Barreyro, PhD, Avery Sampson, BSc, Kathleen Hueneman, Kwangmin Choi, PhD, Susanne Christie, BSc, Dehua Wang, MD, Gang Huang, PhD, Daniel T. Starczynowski, PhD

Blood (2019) 134 (Supplement_1): 2983.

https://doi.org/10.1182/blood-2019-127307

Published: 2019

NARROW

In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms

Kme-0584, a Highly Potent IRAK1/IRAK4/panFLT3 Inhibitor, Is a Promising Clinical Candidate for Hypomethylating Agent Plus Venetoclax Resistant AML/MDS Patients

UBE2N Regulates Oncoprotein Networks in Myeloid Malignancies

Regulation of Metabolic Homeostasis By TRAF6 Contributes to the Leukemia Progression

The Mechanism of Therapy Resistance By Lineage Plasticity in AML and How to Overcome It

In Vivo Ablation of NFκB Cascade Effectors Alleviates Disease Burden in Myeloproliferative Neoplasms

Therapeutic Targeting of FLT3 Gate Keeper Mutation with E2082-0047 in Traditional and a Novel Immunocompetent Murine Adoptive Transfer Model of AML

The Zymogen Form of Caspase-1 Is Required to Fine Tune Excessive Cell-Intrinsic Inflammation in Acute Myeloid Leukemia

Defective Necroptosis Mediates Chemotherapy Resistance in AML

Synthetic Lethal Interactions with IRAK4 Inhibition in Myeloid Malignancies

Targeting CREB-Binding Protein (CREBBP) Overcomes Resistance to Azacitidine and Venetoclax Therapy in Acute Myeloid Leukemia (AML)

Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML

TRIM13 Is a Novel Cell Cycle Hub Regulated By CHAF1B to Promote Acute Myeloid Leukemogenesis

A Circulating Microbial Metabolite Drives the Clonal Expansion of Pre-Leukemic Cells

ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes

IRAK1 Contributes to IRAK4 Inhibitor Resistance Via Non-Canonical Signaling Mechanisms in MDS/AML

Inhibition of Both IRAK1 and IRAK4 Is Required for Complete Suppression of NF-Kb Signaling across Multiple Receptor-Mediated Pathways in MDS and AML

UBE2N Is a Druggable Target and an Essential Ubiquitin-Conjugating Enzyme in Myeloid Malignancies

HHEX expression drives AML development

Cell-Intrinsic Inflammation Drives Progression from Myelodysplastic Syndromes to Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only